Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its eleventh U.S. | The FDA approved the Tecentriq label expansion alongside Natera's Signatera as a companion diagnostic.

Raccontata dafiercepharma.com